Ziprasidone as a Potential Abortive Therapy for Status Migrainosus

Area of Science:

• Neurology
• Pharmacology

Background:

• Status migrainosus is a severe neurologic disorder often requiring hospitalization and multiple medications.
• Atypical antipsychotics, like ziprasidone, have been explored for status migrainosus treatment.

Purpose of the Study:

• To evaluate the efficacy and safety of ziprasidone as an abortive medication for status migrainosus.

Main Methods:

• Retrospective review of 34 patients treated with ziprasidone (10-40 mg) for status migrainosus between 2008-2015.
• Assessed headache severity reduction using a 10-point scale from admission to discharge.
• Monitored medication use, readmission rates, and adverse events.

Main Results:

• Ziprasidone treatment resulted in a significant decrease in headache severity (5.68 ± 3.0 points).
• Ziprasidone was the final abortive medication in 65% of patients.
• The 30-day readmission rate was 12%, with generally well-tolerated side effects.

Conclusions:

• Ziprasidone shows promise as a safe and effective abortive therapy for status migrainosus.
• Further comparative studies are needed to establish ziprasidone's role in standard care.